Hyperion Therapeutics (FRA:0HY) Beneish M-Score : 0.00 (As of Jun. 20, 2024)

View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Hyperion Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Hyperion Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.

Hyperion Therapeutics Beneish M-Score Historical Data

The historical data trend for Hyperion Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics Beneish M-Score Chart

Hyperion Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Beneish M-Score

-2.07

Hyperion Therapeutics Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Beneish M-Score	Get a 7-Day Free Trial													99.98	7.77	-1.53	-2.07	0.78

Competitive Comparison of Hyperion Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Hyperion Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyperion Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyperion Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hyperion Therapeutics's Beneish M-Score falls into.

Hyperion Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hyperion Therapeutics for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 5.1671

0.528 * 0.9685

0.404 * 1.5471

0.892 * 2.2639

0.115 * 1.0416

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.6554

4.679 * -0.150043

0.327 * 1.9038

1.75

This Year (Mar15) TTM:

Last Year (Mar14) TTM:

Total Receivables was €19.9 Mil.
Revenue was 28.822 + 24.984 + 20.332 + 27.302 = €101.4 Mil.
Gross Profit was 25.281 + 21.879 + 17.971 + 24.01 = €89.1 Mil.
Total Current Assets was €146.4 Mil.
Total Assets was €180.2 Mil.
Property, Plant and Equipment(Net PPE) was €1.0 Mil.
Depreciation, Depletion and Amortization(DDA) was €4.1 Mil.
Selling, General, & Admin. Expense(SGA) was €42.8 Mil.
Total Current Liabilities was €35.0 Mil.
Long-Term Debt & Capital Lease Obligation was €15.4 Mil.
Net Income was 6.668 + 5.757 + -25.447 + 12.865 = €-0.2 Mil.
Non Operating Income was 3.848 + -0.174 + -0.225 + -0.003 = €3.4 Mil.
Cash Flow from Operations was 5.175 + 6.476 + -0.346 + 12.131 = €23.4 Mil.

Total Receivables was €1.7 Mil.
Revenue was 14.086 + 13.598 + 11.586 + 5.537 = €44.8 Mil.
Gross Profit was 12.364 + 11.558 + 9.34 + 4.874 = €38.1 Mil.
Total Current Assets was €91.8 Mil.
Total Assets was €104.7 Mil.
Property, Plant and Equipment(Net PPE) was €0.6 Mil.
Depreciation, Depletion and Amortization(DDA) was €3.2 Mil.
Selling, General, & Admin. Expense(SGA) was €28.9 Mil.
Total Current Liabilities was €14.5 Mil.
Long-Term Debt & Capital Lease Obligation was €0.9 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(19.91 / 101.44)	/	(1.702 / 44.807)
	=	0.196274	/	0.037985
	=	5.1671

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(38.136 / 44.807)	/	(89.141 / 101.44)
	=	0.851117	/	0.878756
	=	0.9685

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (146.424 + 0.99) / 180.208)	/	(1 - (91.766 + 0.623) / 104.705)
	=	0.181979	/	0.117626
	=	1.5471

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	101.44	/	44.807
	=	2.2639

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(3.2 / (3.2 + 0.623))	/	(4.05 / (4.05 + 0.99))
	=	0.837039	/	0.803571
	=	1.0416

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(42.812 / 101.44)	/	(28.852 / 44.807)
	=	0.422043	/	0.643917
	=	0.6554

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((15.397 + 34.984) / 180.208)	/	((0.91 + 14.466) / 104.705)
	=	0.279571	/	0.146851
	=	1.9038

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-0.157 - 3.446	-	23.436)	/	180.208
	=	-0.150043

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hyperion Therapeutics has a M-score of 1.75 signals that the company is likely to be a manipulator.

Hyperion Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Hyperion Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyperion Therapeutics (FRA:0HY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hyperiontx.com

Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics (FRA:0HY) Headlines

No Headlines